Spero Therapeutics Inc
Company Profile
Business description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Contact
675 Massachusetts Avenue
14th Floor
CambridgeMA02139
USAT: +1 857 242-1600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
32
Stocks News & Analysis
stocks
Ask the analyst: Can this genius product create the next ASX software king?
stocks
Impact of ANZ’s huge fine
stocks
Acquisition a sign of weakness for overvalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,094.90 | 27.60 | -0.30% |
CAC 40 | 7,809.02 | 9.20 | -0.12% |
DAX 40 | 23,426.28 | 97.04 | 0.42% |
Dow JONES (US) | 46,017.53 | 259.63 | 0.57% |
FTSE 100 | 9,242.77 | 47.11 | 0.51% |
HKSE | 26,908.39 | 469.88 | 1.78% |
NASDAQ | 22,262.90 | 71.06 | -0.32% |
Nikkei 225 | 44,790.38 | 111.89 | -0.25% |
NZX 50 Index | 13,228.38 | 6.51 | -0.05% |
S&P 500 | 6,603.65 | 3.11 | -0.05% |
S&P/ASX 200 | 8,818.50 | 30.00 | -0.34% |
SSE Composite Index | 3,876.34 | 14.48 | 0.37% |